Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CIMETRIX INC (CMXX)
|
Add to portfolio |
|
|
|
| Price: |
$3.50
| | Metrics |
| OS: |
45.0
|
M
| |
7
|
% ROE
|
| Market cap: |
$158
|
M
| |
16
|
% ROIC
|
|
Net cash:
|
$1.62
|
M
| |
$0.04
|
per share
|
|
EV:
|
$156
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$479.0
|
k
| |
325.7
|
x EV/EBITDA
|
|
EBIT
|
$440.0
|
k
| |
354.6
|
x EV/EBIT
|
| EPS |
$0.00
| |
708.4
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 |
| Revenues | 5.2 | 5.6 | 7.8 | 6.8 | 3.1 | 4.1 | 6.4 | 5.6 |
| Revenue growth | -7.2% | -27.9% | 14.9% | 118.8% | -24.9% | -35.2% | 15.0% | 19.0% |
| Cost of goods sold | 2.2 | 2.3 | 3.5 | 1.5 | 1.0 | 1.8 | 3.2 | 2.3 |
| Gross profit | 3.0 | 3.4 | 4.3 | 5.3 | 2.1 | 2.4 | 3.2 | 3.3 |
| Gross margin | 58.0% | 59.6% | 55.3% | 77.7% | 68.9% | 57.2% | 50.1% | 59.1% |
| Sales and marketing | 1.0 | 1.0 | 1.1 | 1.1 | 0.8 | 1.1 | 1.3 | 1.2 |
| Research and development | 0.9 | 1.0 | 1.3 | 0.8 | 0.5 | 0.9 | 1.0 | 1.0 |
| General and administrative | 1.1 | 1.2 | 1.3 | 1.3 | 1.1 | 1.7 | 1.7 | 1.7 |
| EBIT | 0.0 | 0.1 | 0.6 | 2.0 | -0.3 | -1.5 | -1.2 | -1.1 |
| EBIT margin | 0.6% | 1.1% | 7.5% | 29.4% | -11.2% | -36.8% | -19.4% | -19.9% |
| Pre-tax income | 0.0 | 0.1 | 0.6 | 1.9 | -0.5 | -1.7 | -1.3 | -1.1 |
| Income taxes | -1.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 8.1% | 2.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 1.4 | 0.1 | 0.5 | 1.9 | -0.5 | -1.7 | -1.3 | -1.1 |
| Net margin | 26.4% | 1.2% | 6.9% | 28.0% | -15.3% | -42.1% | -20.5% | -20.7% |
| |
| Diluted EPS | $0.03 | $0.00 | $0.01 | $0.04 | ($0.01) | $0.00 | ($0.04) | ($0.04) |
| Shares outstanding (diluted) | 46.1 | 46.4 | 46.7 | 47.4 | 37.8 | 32.5 | 31.9 | 31.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|